Hookipa Pharma Inc (HOOK) - Total Assets
Based on the latest financial reports, Hookipa Pharma Inc (HOOK) holds total assets worth $52.71 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Hookipa Pharma Inc for net asset value and shareholders' equity analysis.
Hookipa Pharma Inc - Total Assets Trend (2017–2025)
This chart illustrates how Hookipa Pharma Inc's total assets have evolved over time, based on quarterly financial data.
Hookipa Pharma Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Hookipa Pharma Inc's total assets of $52.71 Million consist of 99.7% current assets and 0.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 89.4% |
| Accounts Receivable | $2.22 Million | 5.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Hookipa Pharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see HOOK company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hookipa Pharma Inc's current assets represent 99.7% of total assets in 2025, an increase from 94.9% in 2017.
- Cash Position: Cash and equivalents constituted 89.4% of total assets in 2025, up from 83.2% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 5.3% of total assets.
Hookipa Pharma Inc Competitors by Total Assets
Key competitors of Hookipa Pharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Hookipa Pharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.93 | 3.86 | 5.65 |
| Quick Ratio | 3.93 | 3.86 | 5.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $38.52 Million | $79.52 Million | $87.07 Million |
Hookipa Pharma Inc - Advanced Valuation Insights
This section examines the relationship between Hookipa Pharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.48 |
| Latest Market Cap to Assets Ratio | 0.28 |
| Asset Growth Rate (YoY) | -49.3% |
| Total Assets | $41.86 Million |
| Market Capitalization | $11.82 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hookipa Pharma Inc's assets below their book value (0.28x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Hookipa Pharma Inc's assets decreased by 49.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Hookipa Pharma Inc (2017–2025)
The table below shows the annual total assets of Hookipa Pharma Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $41.86 Million | -49.29% |
| 2024-12-31 | $82.55 Million | -48.84% |
| 2023-12-31 | $161.34 Million | -5.35% |
| 2022-12-31 | $170.45 Million | +35.23% |
| 2021-12-31 | $126.05 Million | -32.89% |
| 2020-12-31 | $187.82 Million | +30.66% |
| 2019-12-31 | $143.75 Million | +110.61% |
| 2018-12-31 | $68.25 Million | -7.43% |
| 2017-12-31 | $73.73 Million | -- |
About Hookipa Pharma Inc
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancer… Read more